Drug Trial Radar · NCT07103174
A Study of MG-K10 Humanized Monoclonal Antibody Injection in Subjects With Atopic Dermatitis
Last checked: Nov 20, 2026Latest source record: Aug 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
60
Actual
Start
Jun 30, 2025
Primary completion
Mar 9, 2026
Study completion Apr 29, 2026
Sponsor
- Lead sponsor
- Shanghai Mabgeek Biotech.Co.LtdIndustry
- Sponsor type
- Industry
- First posted
- Aug 5, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a multicenter, randomized, double-blind, parallel controlled phase II study. It is planned to include approximately 60 subjects with moderate to severe atopic dermatitis(AD) to evaluate the efficacy and safety of MG-K10 monotherapy in adult patients with moderate to severe AD, and to observe PK characteristics, PD effects and immunogenicity.
Conditions
- Atopic Dermatitis (AD)
Interventions
MG-K10/PlaceboDrug
To ensure blinding, 4 mL of placebo will be administered subcutaneously at Weeks 4, 12 and 20., for a total of 3 doses.
MG-K10/PlaceboDrug
To ensure blinding,an additional 2 mL of placebo will be administered subcutaneously at Weeks 4, 8, 12, 16 and 20.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The percentage of subjects reaching EASI-75 at 24 weeks of treatmentTime frame: 24 weeks
- The percentage of subjects who achieved the IGA score standard at 24 weeks of treatmentTime frame: 24 weeks
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Tower 5,No.34,Chunxiao Road No.122 Pudong District, Shanghai, 201203.p R. china
Shanghai, Shanghai Municipality, China
Hangzhou First People's Hospital
Zhejiang, 杭州, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.